Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Mauron, B. Lämmle, W. Wuillemin (1998)
Influence of Low Molecular Weight Heparin and Low Molecular Weight Dextran Sulfate on the Inhibition of Coagulation Factor XIa by SerpinsThrombosis and Haemostasis, 80
A. Zaidi, M. Schmoeckel, F. Bhatti, P. Waterworth, M. Tolan, E. Cozzi, G. Chavez, G. Langford, S. Thiru, J. Wallwork, D. White, P. Friend (1998)
Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors.Transplantation, 65 12
R. Rieben, E. Allmen, E. Korchagina, U. Nydegger, F. Neethling, M. Kujundžić, E. Koren, N. Bovin, D. Cooper (1995)
Detection, immunoabsorption, and inhibition of cytotoxic activity of anti‐αGal antibodies using newly developed substances with synthetic Gal α1–3Gal disaccharide epitopesXenotransplantation, 2
V. Young, W. Kaspar-König, D. Tew, J. Wallwork, D. White, R. Pierson (1995)
White blood cells and platelets are integral to the hyperacute rejection of the pig heart by human blood.Transplantation proceedings, 27 1
R. Schmid, A. Zollinger, T. Singer, S. Hillinger, J. Leon-Wyss, O. Schöb, K. Høgåsen, G. Zünd, G. Patterson, W. Weder (1998)
Effect of soluble complement receptor type 1 on reperfusion edema and neutrophil migration after lung allotransplantation in swine.The Journal of thoracic and cardiovascular surgery, 116 1
A. Pierre, A. Xavier, M. Liu, S. Cassivi, T. Lindsay, H. Marsh, Arthur Slutsky, S. Keshavjee (1998)
Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung function.Transplantation, 66 6
M. Yeatman, C. Daggett, W. Parker, G. Byrne, J. Logan, J. Platt, R. Davis (1998)
Complement-mediated pulmonary xenograft injury: studies in swine-to-primate orthotopic single lung transplant models.Transplantation, 65 8
S. Deng, M. Pascual, J. Lou, L. Bühler, H. Wessel, G. Grau, J. Schifferli, P. Morel (1996)
New synthetic sulfated oligosaccharides prolong survival of cardiac xenografts by inhibiting release of heparan sulfate from endothelial cells.Transplantation, 61 9
C. Alvarado, A. Cotterell, K. McCurry, B. Collins, J. Magee, Jamie Berthold, J. Logan, J. Platt (1995)
VARIATION IN THE LEVEL OF XENOANTIGEN EXPRESSION IN PORCINE ORGANSTransplantation, 59
M. Fujishima, T. Omae, Kenzo Tanaka, K. Iino, O. Matsuo, H. Mihara (1986)
Controlled Trial of Combined Urokinase and Dextran Sulfate Therapy in Patients With Acute Cerebral InfarctionAngiology, 37
R. Burger, U. Hadding, H. Schorlemmer, V. Brade, D. Bitter‐Suermann (1975)
Dextran sulphate: a synthetic activator of C3 via the alternative pathway. I. Influence of molecular size and degree of sulphation on the activation potency.Immunology, 29 3
Takaaki Kobayashi, S. Taniguchi, F. Neethling, Alan Rose, Wayne Hancock, Y. Ye, M. Niekrasz, Stanley Kosanke, L. Wright, David White, David Cooper (1997)
Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy.Transplantation, 64 9
P. Macchiarini, G. Mazmanian, R. Oriol, V. Montpreville, É. Dulmet, S. Fattal, J. Libert, S. Doubine, D. Nochy, R. Rieben, P. Dartevelle (1997)
Ex vivo lung model of pig-to-human hyperacute xenograft rejection.The Journal of thoracic and cardiovascular surgery, 114 3
(1998)
using genetically modi ® ed donors
R. Rieben, A. Roos, Y. Muizert, C. Tinguely, A. Gerritsen, M. Daha (1999)
Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation.Blood, 93 3
B. Heckl-Ostreicher, A. Wosnik, M. Kirschfink (1996)
Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection.Transplantation, 62 11
A. Fiane, T. Mollnes, V. Videm, T. Hovig, K. Høgåsen, O. Mellbye, L. Spruce, W. Moore, A. Sahu, John Lambris (1999)
Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenograftsXenotransplantation, 6
V. Koistinen (1993)
Effects of sulphated polyanions on functions of complement factor H.Molecular immunology, 30 2
W. Wuillemin, H. Velthuis, Y. Lubbers, C. Ruig, E. Eldering, C. Hack (1997)
Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma.Journal of immunology, 159 4
A. Bengtsson, C. Svalander, J. Mölne, L. Rydberg, M. Breimer (1998)
Extracorporeal (“ex vivo”) connection of pig kidneys to humans. III. Studies of plasma complement activation and complement deposition in the kidney tissueXenotransplantation, 5
S. Buk (1984)
Simultaneous demonstration of connective tissue elastica and fibrin by a combined Verhoeff's elastic-Martius-scarlet-blue trichrome stain.Stain technology, 59 1
A. Dalmasso, J. Platt (1994)
Potentiation of C1 inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection.Transplantation proceedings, 26 3
M. Blum, Brendan Collins, A. Chang, Jian‐ping Zhang, Sierra Knaus, R. Pierson (1998)
Complement inhibition by FUT‐175 and K76‐COOH in a pig‐to‐human lung xenotransplant modelXenotransplantation, 5
L. Hiebert, J. Liu (1991)
Protective action of polyelectrolytes on endothelium.Seminars in thrombosis and hemostasis, 17 Suppl 1
T. Kroshus, R. Bolman, A. Dalmasso, S. Rollins, E. Guilmette, B. Williams, S. Squinto, W. Fodor (1996)
Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model.Transplantation, 61 10
M. Kirschfink, W. Nürnberger (1999)
C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application.Molecular immunology, 36 4-5
M. Breimer, Staffan Björck, C. Svalander, A. Bengtsson, L. Rydberg, Kari Lie‐Karlsen, P. Attman, M. Aurell, B. Samuelsson (1996)
Extracorporeal (“ex vivo”) connection of pig kidneys to humans. I. Clinical data and studies of platelet destructionXenotransplantation, 3
K. Patel, M. Li, J. Baldeschwieler (1983)
Suppression of liver uptake of liposomes by dextran sulfate 500.Proceedings of the National Academy of Sciences of the United States of America, 80 21
F. Neethling, M. Koscec, R. Oriol, D. Cooper, E. Koren (1999)
A reliable, rapid and inexpensive two-color fluorescence assay to monitor serum cytotoxicity in xenotransplantation.Journal of immunological methods, 222 1-2
C. Flexner, P. Barditch‐Crovo, D. Kornhauser, H. Farzadegan, L. Nerhood, R. Chaisson, K. Bell, K. Lorentsen, C. Hendrix, B. Petty (1991)
Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infectionAntimicrobial Agents and Chemotherapy, 35
S. Meri, M. Pangburn (1990)
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H.Proceedings of the National Academy of Sciences of the United States of America, 87
M. Schmoeckel, Farah Bhatti, A. Zaidi, E. Cozzi, P. Waterworth, M. Tolan, G. Pino-Chavez, Martin Goddard, R. Warner, G. Langford, John Dunning, J. Wallwork, David White (1998)
Orthotopic heart transplantation in a transgenic pig-to-primate model.Transplantation, 65 12
K. McCurry, D. Kooyman, C. Alvarado, A. Cotterell, Michael Martin, J. Logan, J. Platt (1995)
Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injuryNature Medicine, 1
C. Caliezi, W. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, C. Hack (2000)
C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.Pharmacological reviews, 52 1
W. Wuillemin, E. Eldering, F. Citarella, C. Ruig, H. Cate, C. Hack (1996)
Modulation of Contact System Proteases by GlycosaminoglycansThe Journal of Biological Chemistry, 271
L. Hiebert, Ji-min Liu (1994)
Dextran Sulphates Protect Porcine Arterial Endothelial Cells from Free Radical InjuryHuman & Experimental Toxicology, 13
Abstract: Dextran sulfate of 5000 molecular weight (DXS 5000) is known to block complement activation as well as the intrinsic coagulation cascade by potentiation of C1 inhibitor. The effect of DXS 5000 on hyperacute rejection (HAR) was tested in pig‐to‐human xenotransplantation models. For in vitro testing, a cytotoxicity assay was used with the pig kidney cell line PK15 as target cells and fresh, undiluted human serum as antibody and complement source. Ex vivo pig lung perfusion was chosen to assess DXS 5000 in a physiologic model. Pig lungs were perfused with fresh, citrate‐anticoagulated whole human blood to which 1 or 2 mg/ml DXS 5000 were added; the lungs were ventilated and the blood de‐oxygenated. Pulmonary vascular resistance (PVR) and blood oxygenation (ΔpO2) were monitored throughout the experiment. Autologous pig blood and human blood without DXS 5000 served as controls. In the PK15 assay DXS 5000 led to a complete, dose‐dependent inhibition of human serum cytotoxicity with an average IC50 of 43 ± 18 µg/ml (n = 8). Pig lungs perfused with untreated human blood (n = 2) underwent HAR within 105 ± 64 min, characterized by increased PVR, decrease of ΔpO2, and generalized edema. Microscopically, capillary bleeding as well as deposition of human antibodies, complement and fibrin could be observed. Addition of DXS 5000 (n = 4) prolonged lung survival to 170 ± 14 min for 1 mg/ml and 250 ± 42 min for 2 mg/ml, and PVR values as well as edema formation were comparable to control lungs that were perfused with autologous pig blood (n = 2). Activation of complement (activation products in serum, deposition on lung tissue) and the coagulation system (fibrin monomers) were significantly diminished as compared to human blood without DXS 5000. Binding of anti‐Gal antibodies was not influenced, and in vitro experiments showed no evidence of complement depletion by DXS 5000. In conclusion, DXS 5000 is an efficient complement inhibitor in pig‐to‐human xenotransplantation models and therefore a candidate for complement‐inhibitory/anti‐inflammatory therapy – either alone or in combination with other substances – and warrants further investigation.
Xenotransplantation – Wiley
Published: Feb 1, 2001
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.